Hanmi Pharmaceutical (128940.KS) is establishing an "Innovation Growth Division" that will lead domestic and international cash generation through the commercialization of its obesity treatment.
Hanmi Pharmaceutical announced Wednesday that it has carried out a full-scale organizational restructuring to respond to the global pharmaceutical and biotech market environment and efficiently achieve its core business goals. The move is intended to concretize the growth strategy of the "2030 Mid- to Long-Term Vision" previously announced by Hanmi Pharmaceutical Group. At the time, the group had set obesity, anti-aging, digital healthcare, and robotics as new business pillars, presenting a vision to maximize its core new drug and bio businesses while identifying new growth engines in non-pharmaceutical sectors and expanding business linkages across the group.
As the core operating company, Hanmi Pharmaceutical will be reorganized into an integrated four-division system consisting of Innovation Growth, Sustainable Growth, Future Growth, and Growth Support. The biggest change is the creation of the Innovation Growth Division, which will lead cash cow generation. The key idea is to maximize synergy by integrating the New Product Development Center, Marketing Center, Pyeongtaek Manufacturing Center, Pharmaceutical Innovation Center, and Overseas Sales Team to successfully establish the company's obesity treatment — a key priority — both domestically and internationally.
The existing research and development (R&D) center will be reorganized into the Future Growth Division. Three centers — the Obesity and Metabolism Center, Oncology Center, and Convergence Center — will be placed under the division to secure R&D independence and take charge of discovering innovative early-stage new drug candidates. The Domestic Sales Headquarters has been elevated to the Sustainable Growth Division to strengthen its external standing. The Growth Support Division will include the Paltan Manufacturing Center and Business Management Center to back the efficient operation of each growth division. In particular, Hanmi Pharmaceutical said it has built a system that meets global standards by securing the functional independence of its clinical quality assurance (QA) and pharmacovigilance (PV) organizations.
Hanmi Pharmaceutical will also launch a "Portfolio Committee" that strategically decides on large-scale clinical investments. The Clinical Center will be reorganized under the committee, which will serve as a control tower for making final decisions on the company's overall portfolio, including new projects and product adjustments.
"This organizational restructuring focuses on breaking down boundaries between departments and concentrating company-wide capabilities solely on achieving business goals," said Hwang Sang-yeon, CEO of Hanmi Pharmaceutical. "By building an integrated system in which each division is organically connected, we will reinvent ourselves as a global pharmaceutical and biotech company that simultaneously realizes innovative new drug development and sustainable growth."
